Borlongan C V, Koutouzis T K, Freeman T B, Cahill D W, Sanberg P R
Departments of Surgery, Neurology, Psychiatry and Pharmacology, University of South Florida College of Medicine, Tampa 33612, USA.
Brain Res. 1995 Oct 30;697(1-2):254-7. doi: 10.1016/0006-8993(95)00901-2.
Huntington's disease is a progressive neurodegenerative disorder associated with severe degeneration of basal ganglia neurons, especially the intrinsic neurons of the striatum, and characterized by involuntary abnormal choreiform movements and progressive dementia. With the discovery of the gene underlying HD, genetic therapy may be the next logical step towards finding a cure, but no such treatment is currently available. Animal models that closely mimic the neurobiological and clinical symptoms of the disease may offer an alternative approach for the development of new therapies. We report that systemic administration of 3-nitropropionic acid, an inhibitor of the mitochondrial citric acid cycle, results in a progressive locomotor deterioration resembling that of HD. We further demonstrate that manipulating the time course of 3-nitropropionic acid injections leads to sustained hyperactivity (early HD) or hypoactivity (advanced HD). These data suggest that this animal model can be used to test experimental treatments for HD across different stages of the disease.
亨廷顿舞蹈症是一种进行性神经退行性疾病,与基底神经节神经元严重退化有关,尤其是纹状体的内在神经元,并以不自主的异常舞蹈样运动和进行性痴呆为特征。随着亨廷顿舞蹈症相关基因的发现,基因治疗可能是寻找治愈方法的下一个合理步骤,但目前尚无此类治疗方法。能够紧密模拟该疾病神经生物学和临床症状的动物模型可能为开发新疗法提供另一种途径。我们报告称,系统性给予线粒体柠檬酸循环抑制剂3-硝基丙酸会导致类似于亨廷顿舞蹈症的进行性运动功能恶化。我们进一步证明,操纵3-硝基丙酸注射的时间进程会导致持续多动(早期亨廷顿舞蹈症)或活动不足(晚期亨廷顿舞蹈症)。这些数据表明,这种动物模型可用于测试针对亨廷顿舞蹈症不同疾病阶段的实验性治疗方法。